PBIO, Making CBD Oil Truly Water Soluble. A breakthrough that could soon become the industry standard for processing CBD.

Pressure BioSciences, Inc. (OTCQB:PBIO)

Oil based products such as CBD oil are not easily absorbed by the human body. In fact, the human body only absorbs approximately 10% of the  CBD  ingested when infused in beverages and edibles. It has been very difficult for CBD manufacturers to make CBD oil into a water soluble end product that can be fully absorbed by the body. CBD oil manufacturers currently use outdated technology that is inefficient and obsolete. Some CBD processing companies currently make harmful chemical modifications to the CBD oil or use large quantities of chemical detergents to make CBD oil water soluble. These methods have been proven to be ineffective and very costly. These methods do not properly break down the CBD oil resulting in poor quality CBD infused beverages and edibles that lack the desired absorbency in the body that is now being demanded by today’s CBD manufacturers.

Pressure BioSciences has developed a technological breakthrough that makes CBD oil completely water soluble allowing it to be up to 90% absorbed by the body when consumed in CBD beverages and edibles. The company’s UST Ultra Sheer Technology Platform employs a nanotechnology technique that uses ultra-high pressure to sheer oil droplets to such a small size that they effectively dissolve in water. This patented technology uses no harmful chemicals, is highly cost effective, and creates a far  more potent, superior quality CBD end product that can be easily added into a wide variety of CBD infused beverages and edibles increasing the absorbency rate leading to a far more potent product. Pressure BioSciences has designed a patented technology that has been developed for use in the CBD manufacturing industry. The company's product known as the BaroShear K45 is a unique and powerful next generation nanoemulsification system that uses the company's patented Ultra Sheer Technology Platform to process CBD oil into a water soluble end product without the use of harmful and expensive chemicals or detergents. Current methods of processing CBD oil create an end product that is only 10% absorbed by the body when being infused in beverages and edibles. The company’s patented Ultra Sheer Technology Platform employs a nanotechnology technique that uses ultra-high pressure to sheer oil droplets to such a small size that they effectively dissolve in water greatly enhancing the absorption properties of the CBD within the body.

The company has redesigned its UST Technology Platform to be used in the CBD beverage and edibles industries. This new technology called the BaroShear K45 has been specifically designed to meet all of the specifications required for the efficient processing of CBD oil into a completely water soluble end product to be used in the CBD infused beverage and edibles industries. The BaroShear K45 is a unique and powerful next generation nanoemulsification system that uses the company's UST Ultra Sheer Technology Platform to process CBD oil in a cost effective manner without the use of harmful and expensive chemicals and detergents. This BaroShear K45 will be marketed to CBD infused beverage and edibles manufacturers globally. The company already has worldwide sales and distribution channels in place to market and service the BaroShear K45. The company has developed collaboration agreements with several CBD manufacturers that have purchased the BaroShear K45. Leading to strategic partnership opportunities that further benefit the company's research and development efforts. The company's highly absorbent CBD end product gives the company a huge branding opportunity that can lead to substantial contracts and joint venture licensing deals.

The BaroShear K45 uses patented, breakthrough technology that effectively makes Pressure BioSciences' UST processed CBD oil to now be 90% absorbed by the body when infused into beverages and edibles. The BaroShear K45 is quickly becoming the industry standard for the processing of CBD oil. The increased body absorption rate of 90% is leading to a decrease in the amount of CBD oil needed by consumers to feel the same desired effect.  The dramatic increase in the potency of CBD is leading manufacturers to increased profitability as the CBD manufacturers now require much smaller dosing requirements. Pressure BioSciences is creating a paradigm shift in the processing of CBD oil that is leading to exponential sales growth and increased margins for the company.

The company's BaroShear K45 product launch couldn't have come at a more opportune time in the CBD industry's history. With the passage of the 2018 Farm Bill, entrepreneurs are rushing to grow hemp and extract CBD oil that is water soluble and safe for sale to individual consumers or as an ingredient that is infused into beverages. Projected revenue for CBD infused beverages alone is expected to be $220 million by 2022. 

The company recently projected 2020 sales to double from $2.5 million to $5 million as a result of the high demand for the company's BaroShear K45 technology. The company recently announced the purchase of 3 BaroShear K45 systems by several CBD manufacturers increasing the company’s revenue stream substantially. Technology companies with 100% growth rates can easily trade at 10 times annual sales which could easily lead to a $50 million valuation for the company's stock. With less than 2 million shares outstanding the stock may move significantly higher from current levels in the near term as the current market capitalization is a miniscule $6 million offering a substantial upside potential to the company's shares. Trading at only 1 times 2020's forecasted sales PBIO is a very cheap stock compared with its CBD industry peers. The company previously traded on the NASDAQ for upwards of $18.00. The CBD market is hot and valuations are soaring. PBIO is a great way to add the extraordinary growth of the CBD sector to your portfolio.


PBIO has an absolutely incredible stock structure:

Outstanding: 1,926,156

Float: 1,186,936


We give PBIO a thumbs up!























Private Equity Markets was compensated $3,200.00 USD for disseminating this report. This is not investment advice. Please view the disclaimer found on this website.